Craft

UBI Pharma

Stock Price

NT$13.9

2024-05-06

Market Capitalization

NT$1.7 B

2024-05-06

Revenue

NT$538.8 M

FY, 2024

UBI Pharma Summary

Company Summary

Overview
UBI Pharma is a company that develops, manufactures, and sells pharmaceutical products. It offers protein drugs and formulations of molecule products; and develops bio-betters and specialty injectables. The company’s product portfolio includes film-coated, virapine, and efanzy tablets, as well as terbutaline; and levetir concentrate solution for infusion.
Type
Public
Status
Active
Founded
2014
Website
https://www.ubi-pharma.com
Cybersecurity rating
Sectors

Table of Contents

UBI Pharma Financials

Summary Financials

Revenue (H1, 2025)
NT$294.2M
Gross profit (H1, 2025)
NT$305.6M
Net income (H1, 2025)
(NT$53.9M)
Cash (H1, 2025)
NT$145.0M
EBIT (H1, 2025)
(NT$29.3M)
Enterprise value
$2.0B

Footer menu